What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Endocrinology
Eric P. Krenning mainly investigates Internal medicine, Somatostatin, Endocrinology, Octreotide and Radionuclide therapy.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Oncology.
His studies deal with areas such as Receptor, Cancer research, Pancreas and Pathology as well as Somatostatin.
His study in Endocrinology is interdisciplinary in nature, drawing from both Pharmacokinetics, Arginine, El Niño and Biodistribution.
His Octreotide study combines topics in areas such as Radiation therapy, Nuclear medicine, Chemotherapy and Renal function.
Eric P. Krenning combines subjects such as Peptide receptor, Clinical trial and Toxicity with his study of Radionuclide therapy.
His most cited work include:
- Gastroenteropancreatic neuroendocrine tumours. (1225 citations)
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (1042 citations)
- Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival (1038 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Internal medicine, Endocrinology, Somatostatin, Radionuclide therapy and Octreotide.
The various areas that he examines in his Internal medicine study include Gastroenterology and Oncology.
His Endocrinology study incorporates themes from Peptide and Biodistribution.
His work deals with themes such as Cancer research, Kidney and Pharmacology, which intersect with Somatostatin.
His Radionuclide therapy study combines topics from a wide range of disciplines, such as Peptide receptor, Octreotate, DOTA and Toxicity.
His work focuses on many connections between Octreotide and other disciplines, such as Scintigraphy, that overlap with his field of interest in Pathology.
He most often published in these fields:
- Internal medicine (59.66%)
- Endocrinology (40.10%)
- Somatostatin (35.21%)
What were the highlights of his more recent work (between 2014-2021)?
- Internal medicine (59.66%)
- Neuroendocrine tumors (22.25%)
- Radionuclide therapy (29.58%)
In recent papers he was focusing on the following fields of study:
His scientific interests lie mostly in Internal medicine, Neuroendocrine tumors, Radionuclide therapy, Oncology and Gastroenterology.
His Internal medicine research is multidisciplinary, incorporating elements of Endocrinology and Pathology.
His research integrates issues of Clinical endpoint, Quality of life, Surgery and 177Lu-DOTATATE in his study of Neuroendocrine tumors.
His Radionuclide therapy research is multidisciplinary, incorporating perspectives in Cancer research, Peptide receptor, Chromogranin A and Somatostatin receptor, Somatostatin.
His Gastroenterology study integrates concerns from other disciplines, such as Octreotate and Pancreatectomy.
His study explores the link between Octreotide and topics such as Chemotherapy that cross with problems in Adverse effect.
Between 2014 and 2021, his most popular works were:
- Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors (1042 citations)
- ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site (468 citations)
- Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids (295 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Surgery
His primary areas of study are Internal medicine, Neuroendocrine tumors, Radionuclide therapy, Pathology and Endocrinology.
His research in Internal medicine intersects with topics in Gastroenterology and Oncology.
His Neuroendocrine tumors research integrates issues from Radiology and Somatostatin receptor.
His Radionuclide therapy research includes elements of Peptide receptor, Randomized controlled trial, Octreotide, Somatostatin and Toxicity.
In his research, Adverse effect is intimately related to Cancer, which falls under the overarching field of Somatostatin.
He has included themes like Appendiceal neoplasms and MEDLINE in his Endocrinology study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
